Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy

RR Wexler, WJ Greenlee, JD Irvin… - Journal of Medicinal …, 1996 - ACS Publications
The renin-angiotensin system (RAS) is recognized as a key element in blood pressure
regulation and electrolyte/fluid homeostasis. 1 As outlined in Figure 1, the RAS constitutes a …

Angiotensin II blockade: a strategy to slow ageing by protecting mitochondria?

EMV de Cavanagh, F Inserra… - Cardiovascular research, 2011 - academic.oup.com
Protein and lipid oxidation—mainly by mitochondrial reactive oxygen species (mtROS)—
was proposed as a crucial determinant of health and lifespan. Angiotensin II (Ang II) …

Атеросклероз: патогенез, клиника, функциональная диагностика, лечение

РС Карпов, ВА Дудко - 1998 - elibrary.ru
В книге рассмотрены современные патогенные, патофизиологические, клинические,
инструментальные и терапевтические аспекты атеросклеротического повреждения …

Modulation of transforming growth factor-β signaling and extracellular matrix production in myxomatous mitral valves by angiotensin II receptor blockers

A Geirsson, M Singh, R Ali, H Abbas, W Li… - Circulation, 2012 - Am Heart Assoc
Background—Little is known about the pathophysiology of myxomatous degeneration of the
mitral valve, the pathological hallmark of mitral valve prolapse, associated with symptomatic …

The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan

OVEK ANDERSSON, S NELDAM - Blood Pressure, 1998 - Taylor & Francis
This multicentre study compared the antihypertensive effect and tolerability of the novel
angiotensin II antagonist candesartan cilexetil with those of losartan and placebo. Men and …

Sacubitril/valsartan (LCZ696) in heart failure

Y Khder, V Shi, JJV McMurray, MP Lefkowitz - Heart Failure, 2017 - Springer
It has been known since the 1990s that long-term morbidity and mortality is improved in
patients with heart failure with reduced ejection fraction (HFrEF) by treatments that target the …

Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with …

JR Benz, HR Black, A Graff, A Reed… - Journal of human …, 1998 - nature.com
Objective: This study compares the antihypertensive efficacy and tolerability of valsartan, a
novel angiotensin II antagonist, given with hydrochlorothiazide (HCTZ) vs placebo or vs …

A story of two ACEs

U Danilczyk, U Eriksson, MA Crackower… - Journal of molecular …, 2003 - Springer
Abstract According to the World Health Organization predictions cardiovascular diseases
will be the leading cause of death by the year 2020. High blood pressure is a major risk …

Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers.

R Hübner, AM Högemann, M Sunzel… - Journal of human …, 1997 - search.ebscohost.com
Candesartan cilexetil is rapidly and completely hydrolysed to the active compound
candesartan during absorption from the gastrointestinal tract. Candesartan is a potent, long …

Pathogenic role of the renin–angiotensin system in modulating radiation-induced late effects

ME Robbins, DI Diz - International Journal of Radiation Oncology* Biology …, 2006 - Elsevier
With ongoing improvements in cancer therapy and health care, the population of long-term
cancer survivors continues to grow: 62% of adult and 77% of pediatric cancer patients …